Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

Summary

Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety, pharmacokinetics, and preliminary activity of ASTX295 in participants with wild-type TP53 advanced solid tumors. Phase 1 is a dose escalation and dose expansion study design. Sponsor made the strategic decision to not pursue the Phase 2 part of the study.

Timeline

Start

2019-07-11

Primary completion

2023-09-11

Completion

2024-08-15

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

Indications